Connect with us

Cannabis

Leviathan Natural Products Increases Value of Debt Facility

Newsfile

Published

on

Toronto, Ontario–(Newsfile Corp. – July 30, 2020) – Leviathan Natural Products Inc. (CSE: EPIC) (the “Company” or “Leviathan“) announces that effective July 24, 2020, it increased the value of a debt facility with a major shareholder from $5.0 million to $5.5 million at the same terms and conditions as the original agreement.

The terms of the original agreement were initially disclosed in the Company’s news release dated October 31, 2019. The loan will have a maturity date of 15 October, 2021, with the outstanding portion of the principal amount bearing interest at a rate of ten percent (10%) per annum from the date of each advance, payable three times per year: 30 April, 31 August, and 31 December. Leviathan may, at its discretion, repay the balance of principal and/or interest owing at any time without penalty. This financing is meant to be non-dilutive. The Company will primarily use the funding to advance its operations and allow time to complete the refinancing of the building and equipment at its facility in Carthage, Tennessee.

About Leviathan Natural Products

Leviathan Natural Products concentrates on non-psychoactive hemp derived products for the health and wellness market. Leviathan plans on executing a series of buy and build transactions extending across all vertical markets in Canada and internationally. The Company’s global capabilities position it to become a leading multi-jurisdictional cannabinoid producer – one that brings together the best cannabinoid products, brands and expertise from Canada and around the world. The Leviathan portfolio currently comprises Jekyll+Hyde Brand Builders Inc., a marketing services agency specializing in the cannabis/hemp sector; Leviathan US Inc., which intends to begin manufacturing cannabidiol products in August 2020 from its facility in Carthage, Tennessee; LCG Holdings Inc., a hemp cultivation and processing facility in Carmen de Viboral, Colombia, which expects to be operational in calendar Q1 2021; and Woodstock Biomed Inc., which owns a 30-acre property with greenhouse infrastructure in Pelham, Ontario. Development at Woodstock is temporarily suspended pending the adoption of new municipal regulations and zoning by-law amendments imposed by the Town of Pelham that may restrict cannabis and hemp operations.

www.Leviathan-Naturals.com

For more information, contact Martin J. Doane, CEO, Leviathan Natural Products Inc. at 416.903.6691 or Jayne Beckwith, Chief Communications Officer, Leviathan Natural Products Inc. at 416.806.0591.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

# # #

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:

Certain information in this press release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or negatives of these terms and similar expressions. Forward-looking statements are based on certain assumptions, including that renovations at the Carthage, Tennessee facility will be completed sufficiently quickly, the Company being able to secure sufficient hemp biomass to enable commercial production at the Carthage, Tennessee facility, pre-construction and construction activities will be completed at the Carmen de Viboral, Colombia facility by Q1/2021, the Company will obtain equipment financing for construction activities and the purchase of extraction equipment at the Carmen de Viboral facility, and that the Town of Pelham, Ontario and the newly introduced zoning by-law and other related amendments will not unduly restrict the Company’s cannabis and hemp operations. Other assumptions include the successful application to be a licensed cannabis producer and seller, expected revenue will not be less than necessary to fund growth opportunities and the financing of the construction of the greenhouses, results and profits from operations will not be less than required to fund growth opportunities and construction of greenhouses, performance, industry trends, growth opportunities will be available, and general business, economic, competitive, political and social uncertainties will not prevent the Company from conducting its business. While Leviathan considers these assumptions to be reasonable based on information currently available, they are inherently subject to significant business, economic and competitive uncertainties and contingencies and they may prove to be incorrect. Forward‐ looking information speaks only to such assumptions as of the date of this release.

Forward-looking statements also necessarily involve known and unknown risks, including without limitation, risks associated with general economic conditions, adverse industry events, marketing costs, loss of markets, future legislative and regulatory developments, the inability to access sufficient capital on favourable terms, the medical and recreational cannabis industry in Canada and internationally, income tax and regulatory matters, the ability of Leviathan to execute its business strategies, competition, crop failure, currency and interest rate fluctuations, time delays to complete renovations at Carthage, Tennessee facility, the inability to secure sufficient hemp biomass to enable commercial production at the Carthage, Tennessee facility, delays in construction of the Carmen de Viboral, Colombia facility, the inability to obtain equipment financing for the Carmen de Viboral facility, the risk that the newly introduced zoning by-law and other related amendments will unduly restrict the Company’s cannabis and hemp operations in the Town of Pelham, Ontario and other risks. Readers are cautioned that the foregoing is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ from those anticipated. Forward-looking statements are not guarantees of future performance. The purpose of forward‐looking information is to provide the reader with a description of management’s expectations, and such forward‐looking information may not be appropriate for any other purpose.

Except as required by law, Leviathan disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise. Forward- looking statements contained in this news release are expressly qualified by this cautionary statement.

Source: Leviathan Natural Products Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/60869

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Cannabis

Emerald Health Therapeutics Announces Stock Option Grant

Newsfile

Published

on

Vancouver, British Columbia–(Newsfile Corp. – August 3, 2020) – Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) (“Emerald”) announces that it has issued an aggregate of 3,800,000 stock options to employees, consultants and directors at an exercise price of $0.21 per common share for a period of five years. All stock options will vest 25% on the date of grant and 25% on the first three anniversaries of the date of grant. Emerald has also granted an aggregate of 175,000 restricted share units to certain employees. The restricted share units will vest one year from the grant date and convert into common shares of Emerald at a fair market value of $0.21 per common share. The stock options and restricted share units have been granted pursuant to Emerald’s Omnibus Incentive Plan which has been previously approved by Emerald’s shareholders and the TSX Venture.

About Emerald Health Therapeutics

Emerald Health Therapeutics, Inc. is committed to creating new consumer experiences with distinct recreational, medical and wellness-oriented cannabis and non-cannabis products, with an emphasis on life science-based innovation and production excellence. Emerald’s three distinct operating assets are designed to uniquely serve the Canadian marketplace and international opportunities. These assets, all in full production, include: its Metro Vancouver, BC-based greenhouse operation (78,000 square feet) capable of producing organic-certified product; Verdélite, its premium craft cannabis production indoor facility in St. Eustache, Québec (88,000 square feet); and Pure Sunfarms, its 41.3%-owned joint venture in Delta, BC, producing high quality, affordably priced products (1.1 M square feet). Its Emerald Naturals subsidiary has launched a new natural wellness product category with its non-cannabis endocannabinoid-supporting product line and is expanding distribution across Canada.

Please visit www.emeraldhealth.ca for more information or contact:

Jenn Hepburn, Chief Financial Officer
(800) 757 3536 Ext. #5

Emerald Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements.

We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, changes of law and regulations; changes of government; failure to obtain regulatory approvals or permits; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; failure of counter-parties to perform contractual obligations; as well as the risk factors described in Emerald’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management’s current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. Emerald undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/60965

Continue Reading

Cannabis

PAOG Outlines Strategic Next Steps and Corporate Housecleaning Agenda

Newsfile

Published

on

Sandusky, Ohio–(Newsfile Corp. – August 3, 2020) – PAO Group, Inc. (OTC Pink: PAOG) today released a letter from CEO James C. DiPrima to update shareholders on strategic next steps in addition to reviewing corporate housecleaning agenda items. The letter is included in its entirety below:

Cannot view this image? Visit: https://i2.wp.com/grassnews.net/wp-content/uploads/2020/08/paog-outlines-strategic-next-steps-and-corporate-housecleaning-agenda.jpg?w=740&ssl=1
PAOG New Logo

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6729/60946_7bc5829b742ca8b9_001full.jpg

Dear Shareholder,

The last three weeks have been busy for PAOG. Much has been accomplished – a management takeover, and two acquisitions. Expect the momentum to continue. Key contracts moving the company’s acquired cannabis biopharmaceutical technology forward are coming soon.

PAOG anticipates entering into a Contract Research Organization (CRO) agreement as a first step toward initiating an Investigational New Drug Application (IND) to ultimately achieve Food and Drug Administration (FDA) approval for its RespRx Chronic Obstructive Pulmonary Disease (COPD) treatment.

Based on positive results from an informal trial of RexpRX with 25 COVID-19 patients, PAOG also plans to make a Coronavirus Treatment Acceleration Program (CTAP) application after entering into a CRO agreement.

At the same time that we are advancing our cannabis biopharmaceutical technology, we also have some general housekeeping to catch up on. PAOG is behind on its reports required to maintain “current information” status with OTC Markets. We also need to update our website and contact information. We expect to complete all promptly.

A new website is now available. The site is preliminary. Look for continuous updates. Please sign-up for our newsletter and we’ll let you know when to check back.

You can find our new website at www.paogroupinc.com.

Thank you for your interest in our mission to advance the future of medical cannabis technology.

Best Regards,
James C. DiPrima

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

Contact Us:
Jim DiPrima
888-272-6472
info@pao.group

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/60946

Continue Reading

Cannabis

Spyder Cannabis Disclosure Update

Newsfile

Published

on

Vaughan, Ontario–(Newsfile Corp. – July 31, 2020) –  Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder” or the “Company“) provides an update to the filing of disclosure documents as a result of COVID-19:

Filing of Annual Disclosure Documents Due to COVID-19

In a press release dated June 25, 2020, the Company announced, among other things, that due to circumstances created by the COVID – 19 pandemic, it would not be filing its April 30, 2020 quarterly report and management discussion and analysis which was due June 29, 2020.

The Company reports that it has yet to file its April 30, 2020 quarterly report and management discussion and analysis to date.

About Spyder Cannabis Inc.

Spyder is a Cannabis, Vape and CBD retailer that operates in jurisdictions where the products are federally legal in both Canada and the United States. The Company, through its subsidiaries, is a retailer involved in the development of three retail business units. The first is the sale of Cannabis products, the second is the sale of CBD in the United States only, the third is the sale of smoking cessation products in Ontario.

Cautionary Statements

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities laws (“forward-looking statements”). Forward- looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

For more information, please contact:

Spyder Cannabis Inc.
Dan Pelchovitz
President & Chief Executive Officer
Telephone: 1.888.504.7737
Email: corporate@spydercannabis.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/60930

Continue Reading

Trending Online

Grassnews is part of PICANTE Media and Events, a leading media and boutique event organizer in the European Union with a monthly reach of +50,000 readers. The official company (PROSHIRT SRL), has been listed for 4 years in a row among the top 3 Advertising and market research agencies in the local Top Business Romania Microcompanies based on the Financial Reports. Grassnews digests / hand picks the latest news about the CBD / Legal Cannabis industry and serves them to you daily.

Contact us: sales@picante.today

Editorial / PR Submissions

© Grassnews .com 2019 - 2020 - part of PICANTE Media. All rights reserved. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania